Franck Grados
Franck Grados has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Patrice Fardellone
3 shared publications- Vincent Goëb
Department of Rheumatology, University Hospital of Amiens, 80054 Amiens, France
3 shared publications - Patrice Fardellone
Department of Rheumatology, Amiens University Hospital, 80000 Amiens, France
2 shared publications C Marcelli
Department of Rheumatology, Centre Hospitalier Universitaire, Caen, France
1 shared publicationC Roux
Department of Rheumatology, Centre d'Evaluation des Maladies Osseuses, Cochin Hospital, René Descartes University, Paris, France
1 shared publicationChristian Roux
1 shared publication
Latest Publications
- Open Access
- 15 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4631
Relevance of Systematic Pre-Biologic Infectious Screening in Chronic Inflammatory Rheumatic Diseases: A Retrospective Single-Center Study
Background: Systematic infectious screening is recommended before initiation of biologic therapies in chronic inflammatory rheumatic diseases (CIRDs), yet the clinical impact of this strategy in low-prevalence settings remains insufficiently characterized. This study aimed to evaluate the proportion of abnormal findings and their impact on treatment management. Methods: We conducted a retrospective single-center study including adult patients with CIRDs who underwent systematic pre-biologic infectious screening between January 2019 and June 2025. Screening included HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), interferon-γ release assay (IGRA), and chest radiography. The primary outcome was the proportion of abnormal results and their impact on biologic initiation. Results: A total of 418 patients was included (mean age 48.2 ± 14.6 years; 69.1% female). No active HIV, HBV, or HCV infections were detected. Past HBV infection markers were identified in 2.6% of patients, and anti-HCV antibodies in 0.7%, all without detectable viremia. None of these findings required modification of biologic therapy. IGRA positivity was observed in 4.3% of patients and indeterminate results were seen in 3.1%. Preventive antituberculous therapy was initiated in most newly identified IGRA-positive cases, leading to delayed biologic initiation in several patients. Chest radiography yielded limited additional diagnostic value. Conclusions: In this population, systematic pre-biologic infectious screening identified few clinically actionable viral infections, whereas latent tuberculosis screening represented the main determinant of therapeutic modification. These findings support continued emphasis on tuberculosis risk assessment and warrant further prospective studies to evaluate optimized and potentially targeted screening strategies incorporating cost-effectiveness analyses.
- 15 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4631
Open AccessRelevance of Systematic Pre-Biologic Infectious Screening in Chronic Inflammatory Rheumatic Diseases: A Retrospective Single-Center Study
Background: Systematic infectious screening is recommended before initiation of biologic therapies in chronic inflammatory rheumatic diseases (CIRDs), yet the clinical impact of this strategy in low-prevalence settings remains insufficiently characterized. This study aimed to evaluate the proportion of abnormal findings and their impact on treatment management. Methods: We conducted a retrospective single-center study including adult patients with CIRDs who underwent systematic pre-biologic infectious screening between January 2019 and June 2025. Screening included HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), interferon-γ release assay (IGRA), and chest radiography. The primary outcome was the proportion of abnormal results and their impact on biologic initiation. Results: A total of 418 patients was included (mean age 48.2 ± 14.6 years; 69.1% female). No active HIV, HBV, or HCV infections were detected. Past HBV infection markers were identified in 2.6% of patients, and anti-HCV antibodies in 0.7%, all without detectable viremia. None of these findings required modification of biologic therapy. IGRA positivity was observed in 4.3% of patients and indeterminate results were seen in 3.1%. Preventive antituberculous therapy was initiated in most newly identified IGRA-positive cases, leading to delayed biologic initiation in several patients. Chest radiography yielded limited additional diagnostic value. Conclusions: In this population, systematic pre-biologic infectious screening identified few clinically actionable viral infections, whereas latent tuberculosis screening represented the main determinant of therapeutic modification. These findings support continued emphasis on tuberculosis risk assessment and warrant further prospective studies to evaluate optimized and potentially targeted screening strategies incorporating cost-effectiveness analyses.
- 1 August 2021
- Published by Elsevier in Infectious Diseases Now
- Vol. 51 (5) , 497-499
First case of Kingella kingae spondylodiscitis in an elderly man with a molecular characterization of the responsible strain
- 1 August 2021
- Published by Elsevier in Infectious Diseases Now
- Vol. 51 (5) , 497-499
First case of Kingella kingae spondylodiscitis in an elderly man with a molecular characterization of the responsible strain
- Open Access
- 16 October 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (10) , 3319
Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life
Background: Janus kinase inhibitors (JAKis) represent a new alternative to treat rheumatoid arthritis (RA). The objective of this study was to evaluate the effectiveness, tolerance profile, and maintenance of these treatments (tofacitinib and baricitinib) in real life. Methods: All patients in the rheumatology department of Amiens University Hospital treated by JAKis for RA were included from 1 October 2017 to 20 May 2020. Clinical and biological data were provided retrospectively in this observational and single-center study. We aimed to study the JAKi maintenance rate at 12 months and their clinical and biological safety profiles. Results: Fifty-five patients were included. Drug maintenance at 12 months was 67.6%. Factors associated with poorer maintenance were a higher Charlson comorbidity index (HR 1.311 (1.089–1.579); p = 0.0042), a higher age (HR 1.055 (1.015–1.096); p = 0.0067), and corticosteroids therapy at initiation (HR 2.722 (1.006–7.365); p = 0.0487). The clinical and biological safety profile was generally good. Conclusions: Our study found that a higher Charlson index, age, and corticosteroids appeared to be associated with the earlier discontinuation of treatment. JAKis had a response and tolerance profile in real life at least equivalent to that of biological disease-modifying antirheumatic drugs (bDMARDs).
- 16 October 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (10) , 3319
Open AccessTherapeutic Maintenance of Baricitinib and Tofacitinib in Real Life
Background: Janus kinase inhibitors (JAKis) represent a new alternative to treat rheumatoid arthritis (RA). The objective of this study was to evaluate the effectiveness, tolerance profile, and maintenance of these treatments (tofacitinib and baricitinib) in real life. Methods: All patients in the rheumatology department of Amiens University Hospital treated by JAKis for RA were included from 1 October 2017 to 20 May 2020. Clinical and biological data were provided retrospectively in this observational and single-center study. We aimed to study the JAKi maintenance rate at 12 months and their clinical and biological safety profiles. Results: Fifty-five patients were included. Drug maintenance at 12 months was 67.6%. Factors associated with poorer maintenance were a higher Charlson comorbidity index (HR 1.311 (1.089–1.579); p = 0.0042), a higher age (HR 1.055 (1.015–1.096); p = 0.0067), and corticosteroids therapy at initiation (HR 2.722 (1.006–7.365); p = 0.0487). The clinical and biological safety profile was generally good. Conclusions: Our study found that a higher Charlson index, age, and corticosteroids appeared to be associated with the earlier discontinuation of treatment. JAKis had a response and tolerance profile in real life at least equivalent to that of biological disease-modifying antirheumatic drugs (bDMARDs).
- 1 May 2009
- Published by Elsevier in Joint Bone Spine
- Vol. 76 (3) , 241-247
Radiographic methods for evaluating osteoporotic vertebral fractures
- 1 May 2009
- Published by Elsevier in Joint Bone Spine
- Vol. 76 (3) , 241-247
Radiographic methods for evaluating osteoporotic vertebral fractures
- 1 March 2007
- Published by Elsevier in Joint Bone Spine
- Vol. 74 (2) , 133-139
Suggestions for managing pyogenic (non-tuberculous) discitis in adults
- 1 March 2007
- Published by Elsevier in Joint Bone Spine
- Vol. 74 (2) , 133-139
Suggestions for managing pyogenic (non-tuberculous) discitis in adults
- 7 June 2003
- Vol. 32 (20) , 933
[Chronic fluorine intoxication during prolonged treatment with niflumic acid].
- 7 June 2003
- Vol. 32 (20) , 933
[Chronic fluorine intoxication during prolonged treatment with niflumic acid].